Researchers are rapidly focused on retatrutide, a innovative medication from Eli Lilly, as a potential breakthrough in physique management. Distinct from many previous approaches, retatrutide is a dual -action compound targeting equally GLP-1 and GIP, substances that affect satiety and glucose contr